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The role of domiciliary nebulizers in managing
patients with severe COPD
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The diculty of assessing nebulizer responses in chronic obstructive pulmonary disease (COPD) has been
demonstrated before. This study aims to re-examine both the role of domiciliary nebulizers in COPD and also
bronchodilator (BD) assessment in individuals. In a double-blind, randomized, cross-over trial, 19 stable patients
with severe COPD were given the following medication 6-hourly for 2-week periods: (1) nebulized salbutamol
2?5mg with ipratropium 0?5mg and placebo inhalers (MDI) with spacer; (2) placebo nebules and inhaled
salbutamol 400mg with ipratropium 80 mg via MDI with spacer; (3) inhaled salbutamol 400mg with ipratropium
80 mg via MDI with spacer (but no placebo nebulized drugs).
Both nebulized and MDI drugs produced highly significant improvements in forced expiratory volume in 1 sec
(FEV1), forced vital capacity (FVC), specific airways conductance, 6-min walking distance (6MWD) and residual
volume. There were no significant differences between BD responses obtained after active nebulized and active
MDI BDs. From the diary cards, 2 weeks of active nebulized BDs produced a slightly higher median peak
expiratory flow (PEF) than active MDI BDs (236 and 219 lm71, respectively, P=0?01) and slightly less extra
inhaler use (0?8 and 1?1 puffs, respectively, P50?05) but no significant difference in dyspnoea or quality of life
(QOL) scores. There were significant correlations between domiciliary PEF and acute BD-induced changes in FVC
and 6MWD, and also between domiciliary dyspnoea scores and acute changes in both total lung capacity and
6MWD.
In conclusion, nebulized medication conferred little clinical advantage over the regular use of inhalers with
spacers in this group of patients with severe COPD. However, acute changes in total lung capacity, FVC and
6MWD may be useful predictors of the longer-term effects of nebulized BDs in individual patients.
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Nebulizers are generally given in order to quickly and
conveniently deliver large doses of bronchodilators (BD) to
patients with severe airflow obstruction, but their dom-
iciliary use remains controversial. This is partly because of
the possible side-effects from high dose treatment, partly
the fear that patients may rely on the nebulizers rather than
seek medical help when they are acutely ill, and also partly
for financial reasons. Nebulizer solutions of BD are very
expensive and potentially there is a large population of
patients with chronic obstructive pulmonary disease
(COPD) who might like or who might require them.
A number of studies have shown that similar BD effects
can be achieved in COPD patients with metered doseReceived 14 September 2000 and accepted in revised from 2
January 2001.
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0954-6111/01/040265+10 $35?00/0inhalers (MDI)—with or without spacing devices—as with
the more glamorous nebulizers (1–5). Other early studies
have suggested that acute laboratory studies can be used to
identify optimal treatment for individual patients (6,7).
However, large placebo responses to nebulizer treatment
have also been demonstrated in such patients (3).
Unfortunately, most methods used to assess the possible
benefits of nebulized BDs have limitations. Indeed, several
studies reported poor correlations between the effects of BD
drugs on spirometric indices performed in the laboratory
and the subjective responses to these medications during
domiciliary trials (8–10). These authors have suggested that
domiciliary trials should be the prime method of nebulizer
assessment. This has now constituted one of the recom-
mendations in the BTS Guidelines for the use of nebulizers
(11). However, once a patient has a nebulizer at home it is
dicult to retrieve it because of the well recognised, potent
placebo effect of these devices in patients with severe, but
minimally reversible, lung function abnormalities (6,7).
Some patients feel better simply after feeling any cool
nebulized aerosol on their face (8). Possibly supplying a# 2001 HARCOURT PUBLISHERS LTD
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doses from MDIs may produce the same effect. On the
other hand, it is possible that the patients’ perception is
correct and we have been measuring the wrong parameter.
The aims of this present study are to determine whether in
patients with severe COPD:
. BDs produce greater effects when given via a nebulizer
than when given in conventional doses via MDIs both
in the laboratory and in the domiciliary setting;
. there is a significant placebo effect from receiving a
nebulized aerosol;
. acute BD responses of lung function, walking
distances and quality of life score in the laboratory,
can predict longer term effects at home.
Methods
SUBJECTS
Twenty patients with severe but stable COPD, whose
exercise tolerance was limited by dyspnoea, entered this
study. There were 11 male and nine female patients, with an
age range of 57–79 years. All patients had a chronic
productive cough and were either current smokers of at
least 20 pack-years (n=8) or were ex-smokers. They all had
a stable forced expiratory volume in 1 sec (FEV1) over the
preceding 3 months and this was less than 50% predicted
normal. None had cor pulmonale and none had any other
disease which limited either their exercise capacity or the
dose of BD which they could take. No patient had a chest
infection within 1 month of starting the study. All patients
gave written, informed consent for the study, which was
approved by the Lewisham and North Southwark Com-
mittee on Ethical Practice.
PROTOCOL
This was a double-blind, placebo-controlled, randomized,
cross-over trial. For 2-week periods patients took 6-hourly
medication which comprised either:
. salbutamol 2?5mg+ipratropium 0?5mg nebulized and
placebo via MDI (active BDs nebulized);
. saline nebulized and salbutamol 400 mg+ipratropium
80mg via MDI (placebo nebulizer+active BDs by
MDI);
. salbutamol 400 mg and ipratropium 80mg via MDI and
no nebulizer issued (this was always the final period
and was not blinded).
All nebulized solutions were made up to 4ml and
nebulized via an ECOneb 26262 nebulizer–compressor unit
(Medix, Lutterworth, U.K.) which delivers airflow at
8 1min71 at 20 psi. This was used with an Intersurgical
nebulizer and a facemask, which delivers aerosol particles
with a mean mass diameter of 3?46 Zm at 8 lmin71 flow
rate. The active nebulized salbutamol and ipratropium were
given as Combivent. The MDIs were used in conjunctionwith a volumatic spacing device, using two maximal breaths
per puff from the inhaler. The volumatic was wiped with an
anti-static cloth before use.
MEASUREMENTS
During each 2-week study period patients kept diary
records of:
. their peak expiratory flow (PEF)—the best of three
measurements—measured twice daily 1 h after their
morning and evening BDs;
. extra (rescue) inhaled BD usage;
. nocturnal wakings due to dyspnoea;
. dyspnoea (on a scale of 1–5);
. the effect of dyspnoea on their quality of life and daily
activities (on a scale of 1–5).
Altogether, patients were seen in the laboratory on four
occasions. Firstly, they were seen before the study to
practice both the lung function tests and the walks. They
were then issued with the medication and seen after each
study period, when they performed lung function tests and
a 6-min walking test (6MWD) (12–14) 1-h after the same
BDs which they had been taking for that 2-week period. On
each study day:
. both body plethysmograph and spirometer were
calibrated;
. total lung capacity (TLC), residual volume (RV) and
specific airways conductance (sGaw) (derived from
airways resistance) were measured in a constant
volume computerized whole body plethysmograph. Six
measurements of each were made to derive mean values
(these measurements were not made on the last day);
. the best of three technically satisfactory measurements
of FEV1, forced vital capacity (FVC) and slow vital
capacity (SVC) were obtained with a dry spirometer;
. patients completed a Hospital Anxiety-Depression
Score (HAD) (15), a St George’s Respiratory
Questionnaire (SGRQ) (16,17) and a short St
George’s questionnaire (SG30) (18,19);
. 6MWD tests were performed along indoor hospital
corridors. The subjects were accompanied by one of
the investigators who walked in front, encouraging the
patients to walk as fast as they were able and to restart
as soon as possible if they stopped. At the end of the
walks, exertional dyspnoea was recorded on a Borg
score and on a 100mm visual analogue scale, with 0 as
no dyspnoea and 100mm as the worst imaginable
breathlessness.
ANALYSIS
The primary endpoints for the study were FEV1, SGRQ
scores, 6MWD and home PEF values. The secondary
endpoints were TLC and RV, sGaw and diary card
symptom scores. Wilcoxon rank tests were used to compare
measurements before and after BDs and also to compare
the BD-induced changes due to active nebulizer with those
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Spearman’s correlation coecients, was used to compare
the laboratory data obtained from acute BD testing and the
data obtained from the domiciliary use of the nebulizers,
since these data were not linearly distributed.
Results
One patient developed a chest infection and withdrew from
the study, leaving 19 patients, whose demographic details
are shown on Table 1, for evaluation. The mean baseline
FEV1% predicted of the group was 34+8 % (SD) and the
mean 6MWD was 429 m+143 m (SD). Table 2 shows the
highly statistically significant improvements in lung func-
tion and walking distances induced both by nebulized and
by MDI BDs in the group as a whole, with increases in
FEV1, FVC, SVC, sGaw and 6MWD, and decreases in RV,
VAS and Borg post-exertional dyspnoea scores. There were
no statistically significant differences between the changes
in lung function and walking distance induced by the
different regimes in the group as a whole (Fig. 1).
The post-nebulizer FEV1 and FVC were greater than
post-MDI by 200ml or more and 6MWD by 15m in only
three of the 19 patients. The individual changes in FEV1,
FVC and walking distance after nebulized and MDI BDs
are compared by Bland–Altman plots in Fig. 2. In general,
there was no difference between the two methods of
administration in terms of spirometry and walks. AfterTABLE 1. Demographic details of participating COPD patients
Patient Sex Age (years)
FEV
GN F 77
GB M 62
DS F 63
AWh M 74
PD F 63
IC F 77
JG F 62
DD F 67
TD M 70
ED M 71
GD M 79
JT F 75
LE M 64
HL M 65
DK M 71
AW M 71
SC F 63
BB M 57
GS F 64
S: salbutamol; I: ipratropium bromide; B: beclomethazone inhanebulizer, a 200ml or more rise in FEV1, and a 400ml rise
in FVC was seen in 11 subjects and a 30m increase in
6MWD was found in 10 patients. By contrast, after MDI
BD with placebo nebulizer, FEV1 increased by 200ml or
more in 13 patients, FVC increased by 400ml or more in 14
patients and 6MWD increased by 30m or more in eight
COPD patients.
There were no significant differences in the quality of life
scores from the St George’s questionnaires and the HAD
scores after the three study periods (Table 3), apart from a
trivial improvement in the activities score after nebulized
BDs compared with placebo (P50?05). However, compar-
ing nebulizer with MDI only, no significant difference in
activities scores were found. By contrast, the mean of the
morning and evening PEF readings were significantly better
on nebulized BDs compared with MDI medication,
whether MDI drugs were given with or without accom-
panying nebulized placebo. Nevertheless, this difference of
17–18 lmin71 was small in clinical terms and in only two
patients did the mean PEF for the 2-week period exceed
20 lmin71 (22 and 45 lmin71). Patients took slightly more
rescue inhalers when they had no nebulizer at home.
Finally, we tried to establish which acute laboratory test
might predict the domiciliary effect of the BDs. The 6MWD
had a negative correlation with dyspnoea score on the diary
card (r=70?462; P50?05) and a positive correlation with
mean PEF values (r=0?586; P50?01). Post-exertional
dyspnoea also had a negative correlation with PEF
(VAS score r=70?507; P50?01 Borg score r=70?569;Mean baseline Drugs
1% predicted 6MWD
33 271 S,I , B
18 190 S, A, B
24 280 S
32 415 S, I, B
44 529 S, A
26 556 S, I, B
36 464 S, I
32 431 S
26 471 S
44 634 S, A
45 523 S, I, B
31 395 S, I, A, D
30 564 S, I, A
29 466 S, I
46 501 S, B
40 352 S
29 476 S, I, B, A, D
32 533 S, I
45 506 S, I, A, B
ler; A: aminophylline oral; D: diuretic oral.
Table 2. Data from three clinic days
Active nebulized drugs (+placebo MDI) Placebo nebulized drugs (+active MDI drugs)
Baseline median (range) Post-BD median (range) Baseline median (range) Post-BD median (range)
FEV1 (l) 0?78 (0?52–1?38)**** 1?06 (0?6–1?84) 0?88 (0?46–1?42)**** 1?08 (0?58–1?62)
FVC (l) 2?06 (1?52–3?78)**** 2?52 (1?78–4?64) 2?02 (1?22–3?68)**** 2?64 (1?76–4?12)
SVC (l) 2?07 (1?62–3?82)**** 2?46 (1?76–4?48) 1?80 (1?13–3?93)**** 2?61 (1?43–4?48)
TLC (l) 6?20 (4?7–7?4) NS 5?94 (4?4–8?45) 6?20 (10?0–4?5) NS 6?10 (4?3–8?8)
RV (l) 4?10 (2?4–6?9)** 3?40 (2?2–5?4) 4?00 (2?9–6?9)*** 3?50 (2?3–6?1)
Sgaw (s71kPa71) 0?23 (0?12–0?58)**** 0?35 (0?13–0?80) 0?22 (0?13–0?56)*** 0?32 (0?15–0?60)
6 MWD 470 (183–636)*** 507 (289–657) 475 (196–632)*** 529 (290–660)
VAS (mm) 65 (10–90)** 51 (9–81) 65 (6–95)* 43 (4–93)
Borg score 5 (4–6)* 4 (2–6) 5 (3–7)* 4 (2–7)
Wilcoxon rank tests: *P50?05; **P50?01; ***P50?001; ****P50?0001.
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FIG. 1. Median changes in FEV1, FVC, SVC, sGaw, TLC, RV, 6MWD and dyspnoea scores for 19 COPD patients. There is
no significant difference between BD after nebulizer (shaded bars) and after MDI (open bars).
FIG. 2. Bland–Altman plots comparing individual changes after nebulized BD and BD via MDI with nebulized placebo.
Mean change in (a) FEV1, (b) FVC and (c) 6MWD are plotted against difference between changes.
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Fig. 2. (continued)
270 N. EISER ET AL.P50?01). In addition, FVC was positively correlated, with
mean PEF scores (r=0?476; P50?04) and TLC had a
negative correlation with diary card scores for dyspnoea (r
70?559; P50?01). There were no other significant correla-
tions between acute BD testing and domiciliary diary card
results.Discussion
In 1980 (20) a study of five patients with severe COPD
showed that, compared to placebo, nebulized salbutamol
improved PEF, symptom score and rescue inhaler use and
that all patients preferred active nebulized drugs. Since
Table 3. Compares diary card and questionnaire scores
Active nebulized drugs+placebo
MDI
Placebo nebulized drugs+active
MDI
Normal inhalers only
Median Range P1 Median Range P2 Median Range
Diary cards
Mean PEF (lmin71) 228 (124–325) ** 215 (118–315) ** 209 (123–300)
Dyspnoea score 2?8 (1?4–3?2) 2?6 (1?6–3?5) 2?9 (1?5–3?4)
Quality of life score 2?8 (1?2–3?2) 2?8 (1?9–3?5) ** 2?9 (1?5–3?4)
Extra puffs inhaler 0?8 (0–5?1) * 1?1 (0–7?6) ** 1?6 (0–8?7)
Noctural walkings 0 (0–2?3) 0?1 (0–1?2) 0?2 (0–1?4)
Questionnaire scores
SGRQ
Total 61 (35–79) 65 (37–84) 64 (34–81)
Symptoms 75 (32–100) 73 (42–100) 73 (34–100)
Activity 79 (60–93) * 86 (54–100) 80 (60–100)
Impact 43 (23–73) 49 (22–80) 51 (19–77)
StG30 20 (13–28) 21 (12–25) 21 (11–29)
HAD
Anxiety 8 (1–18) 8 (0–18) 7 (2–18)
Depression 6 (2–15) 7 (2–15) 6 (2–15)
Wilcoxon rank scores: P1 compares nebulized BD and placebo; P2 compares nebulized BD and MDI drugs only; no
significant differences between placebo nebulized drugs+MDI and MDI only.
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increased. This is partly due to the patients’ belief that
nebulizers are the most effective treatment for all chest
complaints and that denying them the use of nebulizers
represents sub-optimal treatment, and partly because many
General Practitioners recommend nebulizers without any
formal BD assessment. In addition, recently patients have
been able to order nebulizers via mail order catalogues.
Unfortunately, previous studies have produced conflict-
ing recommendations regarding the most appropriate
method of assessing nebulizers responses. A recent BTS
publication (11) has attempted to give rational guidelines,
but there is a relative paucity of double-blind, placebo-
controlled trials with which to produce evidence-based
recommendations. The present study is one of the few to
attempt this.
EFFECTS OF DOSE AND DEVICE
A number of studies have compared the effects of BDs
inhaled from MDI (with or without spacing devices) with
those from nebulizers (1–5), whilst others have studied
dose–response characteristics of b2-adrenergic stimulants
and anti-cholinergic agents. The results from some of these
studies have suggested that large nebulized doses of BDs
confer little advantage over MDI doses to patients with
stable COPD. For example, it was found that ipratropium
bromide had equipotent acute effects on lung function,
comparing 80 mg and 40mg via MDI with 288 mg and0?1mg, respectively, via a nebulizer in patients
with moderately severe COPD (1,21). In addition, Guna-
wardena et al. (2) reported that in 32 patients with
severe COPD 120 mg ipratropium bromide via an MDI
produced similar BD responses to 125 mg and 500mg via a
nebulizer, both acutely and also when used regularly at
home.
Similar dose–response effects have been reported for b2-
adrenergic agonists in a number of other studies (22–25).
Thus, the effects on spirometry, 6MWD and scores from
the Chronic Respiratory Disease questionnaire of 0?5mg,
1mg and 1?5mg terbutaline inhaled via an MDI were
similar (22), and salbutamol rotacaps 1mg, 2mg and 4mg
gave similar acute spirometric responses, although the
responses lasted longer with the higher doses (23). In an
early study of asthmatic and normal subjects (24), terbuta-
line via MDI and spacer produced greater rises in FEV1
and sGaw than via a nebulizer, dose for dose. A more
recent, open study of 20 patients with severe COPD (25)
also reported that terbutaline 2mg via MDI with spacer
gave similar improvements in FEV1 and FVC to 5mg via a
nebulizer. Our study has produced similar results. The
combined effects of anti-cholinergic agents and b2-adrener-
gic agonists given in regular, relatively small, clinically-
used doses via MDI with spacer produced similar responses
to the larger doses via nebulizer, both acutely in the
laboratory and at home. The most likely reasons are firstly
that there may be differences in deposition of aerosol
inhaled by tidal breathing from the nebulizer compared
with that inhaled with maximal breaths from the MDI plus
272 N. EISER ET AL.spacer, and also that aerosol nebulized during expiration is
wasted. However, our results contrast with those from
studies where the effects of nebulized drugs were compared
with the patients’ normal medication rather than with
standardized, regular MDI with spacer (8–10,29). Thus,
there may be some benefit in taking regular BDs via MDI
with spacer compared with an unregulated regime.
ACUTE OR DOMICILIARY ASSESSMENT
The predictive value of acute changes in spirometry and
other lung function tests has been questioned by several
groups over the past few years (8–10,27) since they often
correlated poorly with patients symptoms when they
received their nebulizers at home. However, subjective
changes may not be a reliable indicator in this situation
because of the marked placebo effect often associated with
nebulizer use. Jenkins et al. (3) reported that all 19 of their
COPD patients felt better using a nebulizer rather than an
MDI although there were no differences in PEF, spiro-
metry, 6MWD, rescue inhaler use or in symptoms. Thus,
the expectation of improvement may have affected the
results of the large, but open, non-randomized studies
reported by O’Driscoll (8,27) and Goldman (10), which
reported poor correlations between acute changes in
spirometry, and domiciliary diary cards and PEF. Although
Goldman’s patients had nebulized placebo for the first
week, this was not blinded and the other two studies were
not placebo-controlled. Nevertheless, the smaller study of
20 COPD patients by Teale et al. (9), which was double-
blind and placebo-controlled, confirmed the lack of
correlation between acute changes in lung function (except
sGaw) and domiciliary PEF. Acute changes in exercise
tolerance were not measured in this study.
Our study was also double-blind and placebo-controlled.
Although most patients reported feeling better when they
had a nebulizer, the diary card data did not confirm this;
the period with and without nebulizer gave similar scores
for all parameters. Our study showed that acute improve-
ments in exercise tolerance, exercise-induced dyspnoea,
FVC and TLC all correlated significantly, although
modestly, with home increases in both perceived dyspnoea
and in PEF. In our hands, therefore, acute changes in FVC
and 6MWD were useful predictors of domiciliary response
to BD medications in these patients. Although TLC can be
used also, this is a more dicult and less reproducible
measurement.
REPRODUCIBILITY OF BD RESPONSES
AND SIGNIFICANT CHANGES
A further problem with interpretation of acute BD
responses is their relatively poor reproducibility (28–33)
and the diculty in deciding what constitutes a significant
BD response. Because of the large within-subject variation
of these responses (30,32), it has been suggested that no
decision about treatment should be made on the strength of
one estimation of BD response. For instance, in one study,
five BD responses over a 21-month period had a within-subject standard deviation of 186ml for FEV1 (32).
Similarly, an intra-subject coecient of variation of 61%
(change as percentage of baseline) and 57% (change as
percentage of predicted) was found for 111 COPD patients
performing six BD responses with FEV1 manoeuvres over
2 years (33). This lack of reproducibility could have
influenced the results from a study such as ours. An
additional problem is that the reproducibility of longer-
term domiciliary responses to BDs of patients with COPD
is entirely unknown.
The within-subject repeatability of the measurements is
also an important consideration in deciding what constitu-
tes a significant change in lung function, exercise capacity
and quality of life scores. A number of studies have
addressed this problem. Both Nisar et al. (34) and the BTS
guidelines on managing COPD (11) have suggested that a
change in FEV1 of 15% or 200ml is significant, whilst
Morrison (26) suggested a change in PEF of 15% or
20mlmin71 is considered significant. In a study of 32 stable
COPD subjects, Hay et al. (35) found that within-subjects
FEV1 varied spontaneously by 140ml and FVC by 390ml,
whilst in an even larger study, Tweedale et al. (31) reported
spontaneous intra-subject variations in FEV1 of 160ml and
in FVC of 330ml. They concluded that a significant
difference should exceed these values. As mentioned before,
the majority of our patients had an increase in FEV1 of
200ml or more and in FVC of 300ml or more. There is less
data concerning the reproducibility of the 6MWD in
patients with COPD. However, Hay’s study (35) showed
an intra-subject variability of 53m within days and 78m
between days, while Jaeschke’s results (22) suggested that a
change of 30–40m was significant. We chose to take 30m as
a significant improvement and, again, half or more of the
patients achieved this following BD treatment in this study.
Unlike asthmatics, COPD patients may have little or no
response to a particular BD. For instance, only 11/20
patients in Morrison’s study (26) had useful responses, in
the study by Nissar (34) 56/127 COPD patients did not
respond to salbutamol and in Teale’s study 11/20 subjects
had a BD-induced increase in FEV1 of only 100ml or less.
The relatively small number of positive responses in the
group makes interpretation of correlations of acute and
domiciliary changes impossible. As mentioned before, in
our study most patients achieved significant improvements
in FEV1, FVC and 6MWD (Fig. 1), making statistical
analysis more meaningful than in previous studies.
In this study we did not demonstrate that the nebulizer
itself had any effect on perceived dyspnoea (diary card data
being similar when patients took active drugs via MDI with
spacer, whether or not they received placebo nebules).
Thus, in these patients there was neither placebo effect from
having the nebulizer nor any effect of the nebulized saline
on lung function or breathlessness.
In conclusion, this placebo-controlled, double-blind
study of 19 patients with stable, severe COPD has shown
that salbutamol and ipratropium bromide given regularly in
conventional, clinical doses by MDI associated with a
spacer produce equivalent BD responses to much larger
nebulized doses. Although domiciliary PEFs were statisti-
cally significantly higher on nebulized BD therapy than on
DOMICILIARY NEBULIZERS IN COPD 273active MDI treatment, the difference was relatively small
and not clinically significant. It is of note that the BTS
guidelines (11) state that, compared with spirometry, PEF
is not a very satisfactory measurement in COPD and
perhaps should not be used to monitor progress at home.
Acute assessment in our laboratory with lung function,
particularly FVC and TLC, and exercise capacity proved
useful predictors of longer-term outcome of treatment.
Since we have found some correlation between both
6MWD and TLC with home dyspnoea scores, we suggest
that either or both of these measurements could be used to
assess BD responses in severe COPD.
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